Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]
Yahooevvelsi günVTRS
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
Yahoo4 gün önceVTRS
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Yahoo4 gün önceVTRS
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...
Yahoo6 gün önceVTRS
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...
Yahoo7 gün önceVTRS
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
Yahoo7 gün önceVTRS
The Real Engine That Could Power Tesla Stock Higher
Forget the humanoid robots for a minute; the most potent catalyst for the stock may already be hitting the streets, and it's growing exponentially.
Yahoo9 gün önceVTRS
Viatris' China Policy Concerns Overstated, UBS Says
Viatris' (VTRS) China business remains resilient despite concerns over the country's new volume-cont
Yahoo15 gün önceVTRS
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Yahoo17 gün önceVTRS
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call
Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s performance to strong commercial execution in Greater China, where investments in established brands and e-commerce channels drove double-digit growth. CEO Scott Smith emphasized that demand for cardiovascular products and the company’s strategic focus on higher-margin generics in North America contrib
Yahoo20 gün önceVTRS
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]
Yahoo21 gün önceVTRS
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Greater China surges 16% as management raises full-year guidance.
Yahoo21 gün önceVTRS
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Yahoo23 gün önceVTRS
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Yahoo24 gün önceVTRS
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.
Yahoo24 gün önceVTRS
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch,...
Yahoo25 gün önceVTRS
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval
Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company’s fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company’s long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal...
Yahoo25 gün önceVTRS